Jilin Aodong Pharmaceutical Group Co., Ltd. specializes in the manufacturing and marketing of pharmaceutical products. Besides, the group offers food products. Net sales break down by activity as follows: - sale of pharmaceutical products (89.4%); - sale of food products (6.8%); - other (3.8%). All sales are in China.

Employees

5,050

Sector

Pharmaceuticals

Calendar

10-23 Ex-dividend date - 0.2 CNY

More about the company

Quotes

Date	Price	Change	Volume
20/10/26	CN¥17.02	-1.22%	8,400,332
19/10/26	CN¥17.23	+0.76%	7,371,352
16/10/26	CN¥17.10	-0.29%	10,803,725
15/10/26	CN¥17.15	-1.72%	9,681,540
14/10/26	CN¥17.45	+0.29%	7,615,715

End-of-day quote Shenzhen S.E.

More quotes

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Jilin Aodong Pharmaceutical Group Co., Ltd.

Company calendar

End-of-day quote Shenzhen S.E. 20/10/2026			5-day change	1st Jan Change
17.02 ^CNY	-1.22%		-2.74%	-12.85%

10-15	Jilin Aodong Pharmaceutical Group Co., Ltd. Announces Interim Profit Distribution Plan for 2026 to Be Implemented (A Shares), payable on October 23, 2026	CI
08-31	Jilin Aodong Pharmaceutical Group Co., Ltd. Proposes Cash Dividend for the First Half of 2026	CI

Market Cap	19.95B 2.99B 2.66B 2.46B 2.23B 4.2B 283B 4.27B 29.57B 11.62B 148B 11.21B 10.97B 472B	P/E 2024	13.1x	P/E 2025	9.57x
Enterprise Value	19.23B 2.88B 2.56B 2.37B 2.15B 4.04B 273B 4.11B 28.5B 11.19B 143B 10.8B 10.57B 455B	EV / Sales 2024	7.76x	EV / Sales 2025	9.49x
Free-Float	66.63%	Yield 2024	2.9%	Yield 2025	2.56%

10-15	Jilin Aodong Pharmaceutical Group Co., Ltd. Announces Interim Profit Distribution Plan for 2026 to Be Implemented (A Shares), payable on October 23, 2026	CI
08-31	Jilin Aodong Pharmaceutical Group Co., Ltd. Proposes Cash Dividend for the First Half of 2026	CI
08-28	Jilin Aodong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
06-09	China Approves Aodong Subsidiary's Levocarnitine Injection	MT
05-21	Jilin Aodong Pharmaceutical Gets China Approval for Supplemental Registration of Heart Drug	MT
05-12	Jilin Aodong Pharmaceutical Group Co., Ltd. Approves Final Cash Dividend on A Shares for the Year 2025, Payable on 08 July 2026	CI
04-29	Jilin Aodong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-20	Jilin Aodong Pharmaceutical's Attributable Profit Jumps 54% in 2025	MT
04-18	Jilin Aodong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-13	Aodong Pharmaceutical's Subsidiary Gets Nod to Market 10 Traditional Chinese Medicines	MT
01-27	Beijing Sun-Novo Pharmaceutical Research Co., Ltd. cancelled the acquisition of Jiangsu Langyan Life Technology Holdings Co., Ltd. from Li Qian, Ganzhou Langyi Investment Center (Limited Partnership) and Other shareholders.	CI
30/10/25	Jilin Aodong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
21/10/25	Aodong Pharmaceutical Gets China Supplementary Nod for Anti-Opioid Medication	MT

1 day	-1.22%
1 week	-2.74%
Current month	-2.24%
1 month	-3.08%
3 months	-5.76%
6 months	-6.53%
Current year	-12.85%

Jilin Aodong Pharmaceutical Group Co., Ltd. Stock

Stocks

000623

CNE000000719

Pharmaceuticals

Valuation: Jilin Aodong Pharmaceutical Group Co., Ltd.

Chart: Jilin Aodong Pharmaceutical Group Co., Ltd.

Latest news: Jilin Aodong Pharmaceutical Group Co., Ltd.

Quotes and Performance

Price Extremes

Managers and Directors: Jilin Aodong Pharmaceutical Group Co., Ltd.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

1 week	16.93	17.56
1 month	16.93	17.91
Current year	16.36	20.93
1 year	16.36	22.08
3 years	12.49	22.08
5 years	12.49	22.08
10 years	12.49	29.43

Manager	Title	Age	Since
Shu Qin Guo CEO	Chief Executive Officer	63	17/07/2017
Kai Yang DFI	Director of Finance/CFO	49	01/05/2004
Shu Yuan Zhang DFI	Director of Finance/CFO	54	18/06/2007

Director	Title	Age	Since
Xiu Lin Li CHM	Chairman	74	18/05/2005
Shu Qin Guo BRD	Director/Board Member	63	01/02/2000
Shu Yuan Zhang BRD	Director/Board Member	54	17/07/2020

Date	Insider	Type	Main position	Quantity	% Market Cap.
25/11/25	An Ning Li	Buy		100	0.0000%
29/07/24	Xiu Lin Li	Buy	Chairman	350,000	0.0302%
29/07/24	Shu Qin Guo	Buy	Chief Executive Officer	320,000	0.0276%

	2024	2025
Net sales	2.61B 391M 348M 322M 292M 549M 37.02B 558M 3.87B 1.52B 19.37B 1.47B 1.44B 61.81B	2.34B 350M 311M 288M 261M 491M 33.12B 499M 3.46B 1.36B 17.33B 1.31B 1.28B 55.29B
Net income	1.55B 232M 207M 192M 174M 326M 22B 332M 2.3B 903M 11.51B 871M 853M 36.73B	2.4B 359M 319M 296M 268M 504M 33.97B 512M 3.55B 1.39B 17.78B 1.35B 1.32B 56.71B
Net Debt	-386M -57.78M -51.43M -47.67M -43.19M -81.17M -5.47B -82.53M -572M -225M -2.86B -217M -212M -9.14B	-724M -108M -96.48M -89.41M -81.02M -152M -10.27B -155M -1.07B -421M -5.37B -407M -398M -17.14B

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
JILIN AODONG PHARMACEUTICAL GROUP CO., LTD.	-1.22%	-2.74%	-15.87%	+5.19%	3.02B
ELI LILLY AND COMPANY	+4.42%	+11.13%	+60.24%	+121.73%	1,106B
JOHNSON & JOHNSON	+2.04%	+4.13%	+33.64%	+69.21%	612B
ABBVIE INC.	+2.25%	+5.41%	+24.62%	+97.77%	500B
ROCHE HOLDING AG	+2.58%	+8.37%	+38.71%	+63.14%	367B
MERCK & CO., INC.	+3.11%	+4.39%	+71.70%	+44.36%	354B
NOVARTIS AG	+1.85%	+6.04%	+21.47%	+49.17%	286B
ASTRAZENECA PLC	+1.76%	+6.07%	+0.43%	+20.98%	256B
AMGEN INC.	+2.26%	+5.12%	+43.08%	+55.66%	230B
GILEAD SCIENCES, INC.	+1.53%	+5.09%	+26.27%	+99.81%	190B
Average	+2.00%	+1.67%	+30.43%	+62.70%	390.32B
Weighted average by Cap.	+2.81%	+2.30%	+41.04%	+80.92%